| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 280 | 2023 |
| Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma HD Kim, GW Song, S Park, MK Jung, MH Kim, HJ Kang, C Yoo, K Yi, ... Gastroenterology 155 (6), 1936-1950. e17, 2018 | 256 | 2018 |
| Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled … YK Kang, MH Ryu, C Yoo, BY Ryoo, HJ Kim, JJ Lee, BH Nam, N Ramaiya, ... The lancet oncology 14 (12), 1175-1182, 2013 | 214 | 2013 |
| A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer C Yoo, JY Hwang, JE Kim, TW Kim, JS Lee, DH Park, SS Lee, DW Seo, ... British journal of cancer 101 (10), 1658-1663, 2009 | 214 | 2009 |
| Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin … C Yoo, K Kim, JH Jeong, I Kim, MJ Kang, J Cheon, BW Kang, H Ryu, ... The Lancet Oncology 22 (11), 1560-1572, 2021 | 170 | 2021 |
| Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer MH Ryu, C Yoo, JG Kim, BY Ryoo, YS Park, SR Park, HS Han, IJ Chung, ... European Journal of Cancer 51 (4), 482-488, 2015 | 137 | 2015 |
| Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis J Kang, I Hwang, C Yoo, K Kim, JH Jeong, HM Chang, SS Lee, DH Park, ... Investigational new drugs 36, 732-741, 2018 | 122 | 2018 |
| Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer C Yoo, DY Oh, HJ Choi, M Kudo, M Ueno, S Kondo, LT Chen, M Osada, ... Journal for immunotherapy of cancer 8 (1), 2020 | 119 | 2020 |
| Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib C Yoo, MH Ryu, BW Kang, SK Yoon, BY Ryoo, HM Chang, JL Lee, ... Journal of clinical oncology 28 (9), 1554-1559, 2010 | 117 | 2010 |
| The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction C Yoo, JE Kim, JL Lee, JH Ahn, DH Lee, JS Lee, S Na, CS Kim, JH Hong, ... Japanese journal of clinical oncology 40 (10), 980-985, 2010 | 105 | 2010 |
| Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP C Yoo, DH Lee, JE Kim, J Jo, DH Yoon, BS Sohn, SW Kim, JS Lee, C Suh Annals of hematology 90, 797-802, 2011 | 100 | 2011 |
| Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational … C Yoo, JH Kim, MH Ryu, SR Park, D Lee, KM Kim, JH Shim, YS Lim, ... Liver Cancer 10 (2), 107-114, 2021 | 84 | 2021 |
| Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma JE Kim, C Yoo, DH Lee, SW Kim, JS Lee, C Suh Annals of hematology 89, 391-397, 2010 | 84 | 2010 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 83 | 2022 |
| Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients BJ Kim, J Hyung, C Yoo, K Kim, SJ Park, SS Lee, DH Park, TJ Song, ... Cancer chemotherapy and pharmacology 80, 209-215, 2017 | 82 | 2017 |
| Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea C Yoo, MH Ryu, J Huh, JH Park, HJ Kang, HS Ahn, Y Lee, MJ Kim, H Lee, ... American journal of hematology 82 (9), 821-823, 2007 | 78 | 2007 |
| Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker H Chae, D Kim, C Yoo, K Kim, JH Jeong, HM Chang, SS Lee, DH Park, ... European Journal of Cancer 120, 31-39, 2019 | 72 | 2019 |
| Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor C Yoo, DH Yoon, C Suh Blood research 49 (3), 148, 2014 | 71 | 2014 |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population A Casadei-Gardini, M Rimini, T Tada, G Suda, S Shimose, M Kudo, ... European Journal of Cancer 180, 9-20, 2023 | 70 | 2023 |
| CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy H Jin, M Ko, D Choi, JH Kim, D Lee, SH Kang, I Kim, HJ Lee, EK Choi, ... Cancer immunology research 8 (7), 912-925, 2020 | 70 | 2020 |
